



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Vistogard Prior Authorization Policy

- Vistogard® (uridine triacetate oral granules – Wellstat Therapeutics)

**REVIEW DATE:** 07/12/2023

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

### **CIGNA NATIONAL FORMULARY COVERAGE:**

#### **OVERVIEW**

Vistogard, a pyrimidine analog, is indicated for the emergency treatment of adult and pediatric patients for the following uses:<sup>1</sup>

- **Fluorouracil or capecitabine overdose**, regardless of the presence of symptoms.
- **Early-onset, severe or life-threatening toxicity** affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity, neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.

As a limitation of use, Vistogard is not recommended for the non-emergent treatment of adverse events associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs.<sup>1</sup> The safety and efficacy of Vistogard initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established.

#### **Disease Overview**

Fluorouracil and capecitabine (a fluorouracil prodrug) are widely used chemotherapeutic agents with potential for significant toxicity. Exaggerated sensitivity to capecitabine or fluorouracil may occur due to genetic variations in certain enzymes, renal impairment, or other causes.<sup>2</sup> Toxicity results in tissue

damage, often manifesting as ulcerative mucositis with neutropenia leading to sepsis, shock, and organ failure. Additionally, central neurotoxicity and cardiac toxicity may occur without any identifiable predisposing factors. Exogenous uridine competes with the toxic metabolite fluorouridine triphosphate for incorporation into RNA in normal tissues, thereby protecting the tissues from toxicity.

## **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Vistogard. All approvals are provided for the duration noted below.

- **Vistogard® (uridine triacetate oral granules – Wellstat Therapeutics) is(are) covered as medically necessary when the following criteria is(are) met for fda-approved indication(s) or other uses with supportive evidence (if applicable):**

### **FDA-Approved Indications**

1. **Capecitabine or Fluorouracil Overdose.** Approve for 7 days.
2. **Capecitabine or Fluorouracil Toxicity, Severe or Life-Threatening.** Approve for 7 days.

### **CONDITIONS NOT COVERED**

- **Vistogard® (uridine triacetate oral granules – Wellstat Therapeutics) is(are) considered experimental, investigational or unproven for ANY other use(s).**

## **REFERENCES**

1. Vistogard® oral granules [prescribing information]. Rockville, MD: Wellstat Therapeutics; February 2017.
2. Ma WW, Saif MW, El-Rayes BF, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. *Cancer*. 2017;123(2):345-356.

## **HISTORY**

<b>Type of Revision</b>	<b>Summary of Changes</b>	<b>Review Date</b>
Annual Revision	No criteria changes.	08/03/2022
Annual Revision	No criteria changes	07/12/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna